Cargando…

Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

BACKGROUND AND RESEARCH QUESTION: Loss of exclusivity of oncology drugs causes an important drop in their price due to the marketing of generic medicines. In this article we study how the price of certain oncology drugs evolves throughout time after the loss of their patent, both in terms of the not...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Sesmero, José M., Smith, Borja, Madurga, Julen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768611/
https://www.ncbi.nlm.nih.gov/pubmed/36628314
http://dx.doi.org/10.33393/grhta.2022.2366
_version_ 1784854209187807232
author Martínez-Sesmero, José M.
Smith, Borja
Madurga, Julen
author_facet Martínez-Sesmero, José M.
Smith, Borja
Madurga, Julen
author_sort Martínez-Sesmero, José M.
collection PubMed
description BACKGROUND AND RESEARCH QUESTION: Loss of exclusivity of oncology drugs causes an important drop in their price due to the marketing of generic medicines. In this article we study how the price of certain oncology drugs evolves throughout time after the loss of their patent, both in terms of the notified price and at a level of the public tenders for the purchase of medicines. METHODS: The variation in the price of oral oncology drugs was assessed from the public information provided by the Interministerial Medicinal Products Pricing Committee (Comisión Interministerial de Precios de los Medicamentos, CIPM) and the data from public tenders for the purchase of medicines. RESULTS: The data show a significant drop in price of the medicines assessed after the expiry of their patent, both at a notified price level (70% of average drop in price in 2.6 years) and at the level of the public tenders (drops exceeding 90% in a year for the most innovative drugs). DISCUSSION: The drop in the price of the oncology drugs after the expiry of their patent is seen in all the medicines assessed. The trends seen allow to predict the evolution of the price of another innovative medicine that is nearing the expiry of its patent (Lenalidomide), with an expected drop in price by 90% with respect to the current price of the innovative drug.
format Online
Article
Text
id pubmed-9768611
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AboutScience
record_format MEDLINE/PubMed
spelling pubmed-97686112023-01-09 Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines Martínez-Sesmero, José M. Smith, Borja Madurga, Julen Glob Reg Health Technol Assess Original Research Article BACKGROUND AND RESEARCH QUESTION: Loss of exclusivity of oncology drugs causes an important drop in their price due to the marketing of generic medicines. In this article we study how the price of certain oncology drugs evolves throughout time after the loss of their patent, both in terms of the notified price and at a level of the public tenders for the purchase of medicines. METHODS: The variation in the price of oral oncology drugs was assessed from the public information provided by the Interministerial Medicinal Products Pricing Committee (Comisión Interministerial de Precios de los Medicamentos, CIPM) and the data from public tenders for the purchase of medicines. RESULTS: The data show a significant drop in price of the medicines assessed after the expiry of their patent, both at a notified price level (70% of average drop in price in 2.6 years) and at the level of the public tenders (drops exceeding 90% in a year for the most innovative drugs). DISCUSSION: The drop in the price of the oncology drugs after the expiry of their patent is seen in all the medicines assessed. The trends seen allow to predict the evolution of the price of another innovative medicine that is nearing the expiry of its patent (Lenalidomide), with an expected drop in price by 90% with respect to the current price of the innovative drug. AboutScience 2022-05-13 /pmc/articles/PMC9768611/ /pubmed/36628314 http://dx.doi.org/10.33393/grhta.2022.2366 Text en https://creativecommons.org/licenses/by-nc/4.0/Global & Regional Health Technology Assessment - ISSN 2283-5733 - www.aboutscience.eu/grhta (http://www.aboutscience.eu/grhta) © 2022 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu (http://www.aboutscience.eu)
spellingShingle Original Research Article
Martínez-Sesmero, José M.
Smith, Borja
Madurga, Julen
Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title_full Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title_fullStr Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title_full_unstemmed Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title_short Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
title_sort analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768611/
https://www.ncbi.nlm.nih.gov/pubmed/36628314
http://dx.doi.org/10.33393/grhta.2022.2366
work_keys_str_mv AT martinezsesmerojosem analysisoftheevolutionofthepriceofoncologydrugsafterthelossoftheirpatentandthemarketingofgenericmedicines
AT smithborja analysisoftheevolutionofthepriceofoncologydrugsafterthelossoftheirpatentandthemarketingofgenericmedicines
AT madurgajulen analysisoftheevolutionofthepriceofoncologydrugsafterthelossoftheirpatentandthemarketingofgenericmedicines